Sign In

Phil Grayeski

Partner @ KdT Ventures, Co-Founder @ Torque Bio

Phil Grayeski is a prominent figure in the biotech investment and entrepreneurship space. He currently serves as a Partner at KdT Ventures, where he invests in early-stage biotech companies across various sectors including human health, climate technologies, and consumer bio.12

Professional Experience

Grayeski's career spans both investment and entrepreneurship:

Investment:

  • Partner at KdT Ventures (October 2021 - Present)
  • Previously held positions of Principal and Venture Associate at KdT Ventures

Entrepreneurship:

  • Co-Founder of Torque Bio (June 2018 - Present)
  • Previously involved in spinning out two therapeutics companies, StrideBio and Ribometrix, from UNC-Chapel Hill

Board Positions

Grayeski serves on the board of several biotech companies, including:

  • Cyberdontics (February 2022 - Present)
  • Andes (May 2020 - Present)
  • Vecprobio, Inc. (August 2022 - Present)

He has also previously held board positions at Transcera Inc. and Dimension Inx.1

Education

Grayeski has a strong academic background:

  • Ph.D. in Genetics from the University of North Carolina at Chapel Hill (2017 - 2021)
  • M.Phil in Bioscience Enterprise from the University of Cambridge (2014 - 2015)
  • B.S. in Genetics and Chemistry from the University of Georgia (2010 - 2014)

He is also an MD-PhD trainee at UNC-Chapel Hill's MSTP program, currently on leave from the MD training.2

Achievements

  • Named a 2013 Barry M. Goldwater Scholar while at the University of Georgia3
  • Recipient of the CR Lowe Carpe Diem - Life Science Young Entrepreneur of the Year award
  • NHLBI F30 Fellowship recipient1

Grayeski is known for his focus on finding new companies in overscienced yet underfunded ecosystems outside traditional biotech hubs. His approach at KdT Ventures emphasizes being the "kindest" in the space, leveraging his operator background to provide valuable support to the companies they invest in.2

Highlights

Jul 19 · linkedin

Context is key. SURGE Therapeutics, the intraoperative immunotherapy company, is altering the context of 1st line cancer care, surgical resection, by reprogramming the patient's immune system. SURGE’s platform inhibits the immunosuppression of wound healing while augmenting the body's immune system to “search and destroy” local and distal tumors. We are most excited about deepening the participation of surgical oncologists, a relatively untapped clinical resource, in providing the definitive treatment in cancer. With the first two patients dosed, KdT Ventures is eager to see how Michael Goldberg and the Surge team redefine early cancer care.

Grateful to be working with Kouki Harasaki, PhD and Bioluminescence Ventures, Robert Long, Intuitive Ventures, Khosla Ventures, 8VC, Pitango, and Camford Capital on this opportunity.

Related Questions

What are Phil Grayeski's main responsibilities at Cyberdontics?
How did Phil Grayeski's background in genetics influence his career in biotech?
What is the focus of KdT Ventures under Phil Grayeski's leadership?
How did Phil Grayeski's experience at UNC-Chapel Hill shape his professional path?
What are some notable achievements of Phil Grayeski in the biotech industry?
Phil Grayeski
Phil Grayeski, photo 1
Add to my network

Location

Raleigh-Durham-Chapel Hill Area